Controversies in Cancer Stem Cells: Targeting Embryonic Signaling Pathways

Por Takebe, Naoko, Ivy, S. Percy
Publicado no Clin Cancer Res (2010)

Confronting the Care Delivery Challenges Arising from Precision Medicine

Por Kohn, Elise C., Ivy, S. Percy
Publicado no Front Oncol (2016)

Molecular Conversations and the Development of the Hair Follicle and Basal Cell Carcinoma

Por Harris, Pamela Jo, Takebe, Naoko, Ivy, S. Percy
Publicado em 2010

Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition

Por Takebe, Naoko, Warren, Ronald Q, Ivy, S Percy
Publicado em 2011

Approaches to Phase 1 Clinical Trial Design Focused on Safety, Efficiency and Selected Patient Populations: A Report from the Clinical Trial Design Task Force of the National Cance...

Por Ivy, S. Percy, Siu, Lillian L., Garrett-Mayer, Elizabeth, Rubinstein, Larry
Publicado no Clin Cancer Res (2010)

Phase I trial of daily triapine in combination with cisplatin chemotherapy for advanced-stage malignancies

Por Kunos, Charles A., Chu, Edward, Beumer, Jan H., Sznol, Mario, Ivy, S. Percy
Publicado no Cancer Chemother Pharmacol (2016)

Phase I Trial of Triapine–Cisplatin–Paclitaxel Chemotherapy for Advanced Stage or Metastatic Solid Tumor Cancers

Por Kunos, Charles A., Chu, Edward, Makower, Della, Kaubisch, Andreas, Sznol, Mario, Ivy, Susan Percy
Publicado no Front Oncol (2017)

The effect of hepatic impairment on outcomes in phase 1 clinical trials in cancer subjects

Por Mansfield, Aaron S., Rudek, Michelle A., Vulih, Diana, Smith, Gary L., Harris, Pamela Jo, Ivy, S. Percy
Publicado no Clin Cancer Res (2016)

Theoretical and Practical Application of Traditional and Accelerated Titration Phase I Clinical Trial Designs: The Wayne State University Experience

Por Heath, Elisabeth I., LoRusso, Patricia M., Ivy, S. Percy, Rubinstein, Larry, Christian, Michaele C., Heilbrun, Lance K.
Publicado em 2009

Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical update

Por Takebe, Naoko, Miele, Lucio, Harris, Pamela Jo, Jeong, Woondong, Bando, Hideaki, Kahn, Michael, Yang, Sherry X., Ivy, S. Percy
Publicado no Nat Rev Clin Oncol (2015)

Effect of Renal Dysfunction on Toxicity in Three Decades of Cancer Therapy Evaluation Program–Sponsored Single-Agent Phase I Studies

Por Beumer, Jan H., Ding, Fei, Tawbi, Hussein, Lin, Yan, Viluh, Diana, Chatterjee, Indrani, Rinker, Matthew, Chow, Selina L., Ivy, S. Percy
Publicado no J Clin Oncol (2016)

Phase I Clinical Trials in Acute Myeloid Leukemia: 23-Year Experience From Cancer Therapy Evaluation Program of the National Cancer Institute

Por Zeidner, Joshua F., Karp, Judith E., Blackford, Amanda L., Foster, Matthew C., Dees, E. Claire, Smith, Gary, Ivy, S. Percy, Harris, Pamela
Publicado no J Natl Cancer Inst (2015)

Phase II study of cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (NCI # 7097)

Por Ramalingam, Suresh S., Belani, Chandra P., Mack, Philip C., Vokes, Everett E., Longmate, Jeffrey, Govindan, Ramaswamy, Koczywas, Marianna, Ivy, S. Percy, Gandara, David R.
Publicado em 2010

Historical Controls for Metastatic Pancreatic Cancer: Benchmarks for Planning and Analyzing Single Arm Phase II Trials

Por Philip, Philip A., Chansky, Kari, LeBlanc, Michael, Rubinstein, Lawrence, Seymour, Lesley, Ivy, S. Percy, Alberts, Steven R., Catalano, Paul J., Crowley, John
Publicado no Clin Cancer Res (2014)

Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee

Por Seymour, Lesley, Groshen, Susan, Rosner, Gary L., Sullivan, Daniel M., Spriggs, David R., Reeves, Steven, Gravell, Amy, Ivy, S. Percy, Ratain, Mark J.
Publicado no Clin Cancer Res (2015)

Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors

Por Hubbard, Joleen, Erlichman, Charles, Toft, David O., Qin, Rui, Stensgard, Bridget A., Felten, Sara, Eyck, Cynthia Ten, Batzel, Gretchen, Ivy, S. Percy, Haluska, Paul
Publicado em 2010

Challenges Facing Early Phase Trials Sponsored by the National Cancer Institute: An Analysis of Corrective Action Plans to Improve Accrual

Por Massett, Holly A., Mishkin, Grace, Rubinstein, Larry, Ivy, S. Percy, Denicoff, Andrea, Godwin, Elizabeth, DiPiazza, Kate, Bolognese, Jennifer, Zwiebel, James A., Abrams, Jeffrey S.
Publicado no Clin Cancer Res (2016)

First-in-Human Phase 0 Trial of Oral 5-iodo-2-pyrimidinone-2′-deoxyribose (IPdR) in Patients with Advanced Malignancies

Por Kummar, Shivaani, Anderson, Larry, Hill, Kimberly, Majerova, Eva, Allen, Deborah, Horneffer, Yvonne, Ivy, S. Percy, Rubinstein, Larry, Harris, Pamela, Doroshow, James H., Collins, Jerry M.
Publicado em 2013

Developing Standards for Breakthrough Therapy Designation in Oncology

Por Horning, Sandra J., Haber, Daniel A., Selig, Wendy K.D., Ivy, S. Percy, Roberts, Samantha A., Allen, Jeff D., Sigal, Ellen V., Sawyers, Charles L.
Publicado em 2013

Predictors of early treatment discontinuation in patients enrolled on Phase I oncology trials

Por Hyman, David M., Eaton, Anne A., Gounder, Mrinal M., Pamer, Erika G., Pettiford, Jasmine, Carvajal, Richard D., Ivy, S. Percy, Iasonos, Alexia, Spriggs, David R.
Publicado no Oncotarget (2015)